Skip to Content

Personalized Medicine on the Horizon for Atopic Dermatitis

At EADV 2023, dermatologist Marjolein de Bruin-Weller discusses new developments in atopic dermatitis treatment, including the approval of the IL-13 inhibitor lebrikizumab and the study of OX40 inhibitors. Long-term safety data on dupilumab and tralokinumab are presented, and new topical treatments, such as JAK inhibitors and PDE4 inhibitors, are emerging.

Marjolein de Bruin-Weller

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top